-+ 0.00%
-+ 0.00%
-+ 0.00%

Medicus Pharma seeks FDA orphan drug designation for SkinJect in Gorlin syndrome

PUBT·04/17/2026 11:30:36
Listen to the news
Medicus Pharma seeks FDA orphan drug designation for SkinJect in Gorlin syndrome
  • Medicus Pharma submitted an orphan drug designation application to FDA for SkinJect to treat basal cell carcinoma in patients with Gorlin Syndrome.
  • Filing targets an orphan indication estimated at about 11,000 US patients.
  • Orphan designation, if granted, could support a faster regulatory path for SkinJect and provide 7 years of US market exclusivity on approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604170730PRIMZONEFULLFEED9691830) on April 17, 2026, and is solely responsible for the information contained therein.